NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
Aragon Pharmaceuticals, Inc.
University of Texas Southwestern Medical Center
Brigham and Women's Hospital
Servier
Janssen Research & Development, LLC